NCT02713243View on ClinicalTrials.gov

To Assess Safety, Tolerability and Efficacy of LJN452 in Patients With Primary Bile Acid Diarrhea.

PHASE2CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

January 16, 2016

Primary Completion Date

January 25, 2018

Study Completion Date

January 25, 2018

Conditions
Primary Bile Acid Diarrhea
Interventions
DRUG

LJN452

Capsules containing LJN452

DRUG

Placebo to LJN452

Capsules containing placebo to LJN452

Trial Locations (4)

55905

Novartis Investigative Site, Rochester

HA1 3UJ

Novartis Investigative Site, Harrow

W2 1PG

Novartis Investigative Site, London

S10 2JF

Novartis Investigative Site, Sheffield

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY